Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer
暂无分享,去创建一个
G. Mills | G. Hortobagyi | K. Do | F. Meric-Bernstam | A. González-Angulo | M. Bondy | M. Chávez-MacGregor | P. Thompson | Huiqin Chen | M. Karuturi | G. Blumenschein | S. Tsavachidis
[1] G. Mills,et al. PI3K pathway-directed therapeutic strategies in cancer. , 2010, Current opinion in investigational drugs.
[2] Mitsutaka Kadota,et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. , 2009, Cancer research.
[3] P. Pandolfi,et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.
[4] G. Mills,et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.
[5] Funda Meric-Bernstam,et al. Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. V. Vande Woude,et al. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer , 2009, Clinical Cancer Research.
[7] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[8] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[9] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[10] Yiling Lu,et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.
[11] E. Tok,et al. Expression of the c‐Met in advanced epithelial ovarian cancer and its prognostic significance , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[12] Xin Huang,et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.
[13] E. Lengyel,et al. C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu , 2005, International journal of cancer.
[14] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[15] G. Watkins,et al. The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer , 2004, Clinical Cancer Research.
[16] J. Christensen,et al. c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.
[17] B. Zbar,et al. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.
[18] O. Stål,et al. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.
[19] K. Miyazaki,et al. Expression of the hepatocyte growth factor/c‐Met pathway is increased at the cancer front in breast carcinoma , 2001, Pathology international.
[20] E. Rimm,et al. Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.
[21] T. Nakajima,et al. Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance , 1996, Japanese journal of cancer research : Gann.
[22] M. Ogawa,et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.
[23] J. Bruix,et al. c‐met mRNA overexpression in human hepatocellular carcinoma , 1994, Hepatology.
[24] W. Birchmeier,et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Rubin,et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.
[26] E. Gherardi,et al. Hepatocytes and scatter factor , 1990, Nature.
[27] K. Tashiro,et al. Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.
[28] M. Okigaki,et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. , 1989, Biochemical and biophysical research communications.
[29] G. Michalopoulos,et al. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. , 1989, Cancer research.
[30] Michael Stoker,et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.